Confidence among biopharmaceutical executives has climbed to its highest level in four years, signaling the industry's ability to adapt to an increasingly complex geopolitical, regulatory, and commercial environment.

According to GlobalData's State of the Biopharmaceutical Industry 2026 (Mid-Year Update), which surveyed 157 pharmaceutical professionals globally, 55% of respondents expressed optimism or strong optimism about industry growth over the next 12 months. 

The figure represents a significant improvement from 2023, when concerns around funding availability, rising capital costs, and economic uncertainty weighed heavily on industry sentiment.

The improvement comes even as pharmaceutical companies continue to grapple with U.S. tariff threats, Most Favored Nation (MFN) drug pricing reforms, Inflation Reduction Act (IRA)-related price negotiations, and the looming patent cliff. 

Hannah Hans, Head of Pharma Strategic Intelligence at GlobalData, said: "What makes this recovery noteworthy is what is driving it. This is not a story of improved external conditions. The US tariffs, Most Favored Nation (MFN) pricing reform, Inflation Reduction Act (IRA)-related drug price negotiations, and the looming patent cliff have not gone away. It is a story of an industry that absorbed significant disruption, made challenging decisions, and reprioritized."

GlobalData noted that companies have spent the past few years restructuring operations, refining development priorities, optimizing costs, and adapting their strategies to navigate uncertainty.

Hans added: "Companies did not just wait for conditions to improve; strategic and focused choices were made. The optimism we are seeing now is grounded in that, and that makes it more credible."

The report also points to a sharp increase in dealmaking activity. Pharmaceutical M&A deal value rose 71% year-on-year in the first quarter of 2026, while biotechnology IPO activity surged 210%. Funding sentiment has also improved, with 52% of respondents now optimistic about biotech funding recovery over the next year, compared with 39% in December 2025. 

According to Hans, the surge in transactions reflects growing confidence in the industry's scientific and commercial prospects. 

"Deal activity at this level is always telling. When companies are willing to commit capital at scale, it means they have done the work internally and like what they see. The science in cardiometabolic, oncology, and neurology is genuinely compelling right now, and the market is pricing that in,” Hans concluded.